Richard Furie

24.2k total citations · 13 hit papers
236 papers, 15.5k citations indexed

About

Richard Furie is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Richard Furie has authored 236 papers receiving a total of 15.5k indexed citations (citations by other indexed papers that have themselves been cited), including 200 papers in Rheumatology, 126 papers in Radiology, Nuclear Medicine and Imaging and 110 papers in Immunology. Recurrent topics in Richard Furie's work include Systemic Lupus Erythematosus Research (194 papers), Monoclonal and Polyclonal Antibodies Research (126 papers) and T-cell and B-cell Immunology (67 papers). Richard Furie is often cited by papers focused on Systemic Lupus Erythematosus Research (194 papers), Monoclonal and Polyclonal Antibodies Research (126 papers) and T-cell and B-cell Immunology (67 papers). Richard Furie collaborates with scholars based in United States, United Kingdom and Sweden. Richard Furie's co-authors include Joan T. Merrill, Daniel J. Wallace, Thomas Dörner, Michelle Petri, William W. Freimuth, Kenneth Kalunian, Ellen M. Ginzler, Raj Tummala, William Stohl and Z. John Zhong and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Richard Furie

220 papers receiving 15.1k citations

Hit Papers

Rituximab for rheumatoid ... 2006 2026 2012 2019 2006 2011 2012 2019 2016 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks
    2006 1.3k citations Richard Furie et al. Arthritis & Rheumatism profile →
  2. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
    2011 1.1k citations Richard Furie, Michelle Petri et al. Arthritis & Rheumatism profile →
  3. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study
    2012 972 citations Brad H. Rovin, Richard Furie et al. Arthritis & Rheumatism profile →
  4. Trial of Anifrolumab in Active Systemic Lupus Erythematosus
    2019 778 citations Eric F. Morand, Richard Furie et al. profile →
  5. Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
    2016 618 citations Richard Furie, Munther A. Khamashta et al. Arthritis & Rheumatology profile →
  6. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
    2020 549 citations Richard Furie, Brad H. Rovin et al. profile →
  7. Novel paradigms in systemic lupus erythematosus
    2019 406 citations Thomas Dörner, Richard Furie profile →
  8. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
    2016 382 citations Munther A. Khamashta, Joan T. Merrill et al. Annals of the Rheumatic Diseases profile →
  9. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
    2018 356 citations Daniel J. Wallace, Richard Furie et al. profile →
  10. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
    2019 289 citations Richard Furie, Eric F. Morand et al. profile →
  11. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
    2022 237 citations Richard Furie, Brad H. Rovin et al. Annals of the Rheumatic Diseases profile →
  12. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
    2022 130 citations David Jayne, Brad H. Rovin et al. Annals of the Rheumatic Diseases profile →
  13. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)
    2023 79 citations Eric F. Morand, Michelle Petri et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard Furie United States 58 11.9k 8.9k 5.8k 1.8k 1.5k 236 15.5k
Joan T. Merrill United States 56 10.4k 0.9× 7.8k 0.9× 4.2k 0.7× 1.4k 0.8× 1.2k 0.8× 214 13.8k
William Stohl United States 51 6.0k 0.5× 6.8k 0.8× 3.6k 0.6× 942 0.5× 821 0.5× 159 10.0k
Jill P. Buyon United States 74 9.8k 0.8× 7.1k 0.8× 2.9k 0.5× 599 0.3× 1.0k 0.7× 320 17.1k
Kenneth Kalunian United States 46 6.5k 0.5× 4.5k 0.5× 2.4k 0.4× 1.1k 0.6× 799 0.5× 156 8.2k
Ellen M. Ginzler United States 44 7.9k 0.7× 4.6k 0.5× 2.9k 0.5× 534 0.3× 1.1k 0.7× 98 9.5k
Frédéric Houssiau Belgium 41 4.6k 0.4× 3.6k 0.4× 1.6k 0.3× 1.2k 0.7× 993 0.7× 149 7.8k
Gunnar Sturfelt Sweden 52 5.1k 0.4× 4.7k 0.5× 1.3k 0.2× 755 0.4× 810 0.5× 165 8.3k
Gabor G. Illei United States 48 4.3k 0.4× 4.6k 0.5× 1.4k 0.2× 1.0k 0.6× 648 0.4× 99 9.3k
Iva Gunnarsson Sweden 48 4.3k 0.4× 3.9k 0.4× 1.2k 0.2× 568 0.3× 685 0.5× 211 6.6k
Anne Davidson United States 47 3.2k 0.3× 4.5k 0.5× 1.3k 0.2× 766 0.4× 446 0.3× 155 7.4k

Countries citing papers authored by Richard Furie

Since Specialization
Citations

This map shows the geographic impact of Richard Furie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Furie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Furie more than expected).

Fields of papers citing papers by Richard Furie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Furie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Furie. The network helps show where Richard Furie may publish in the future.

Co-authorship network of co-authors of Richard Furie

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Furie. A scholar is included among the top collaborators of Richard Furie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Furie. Richard Furie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
McDonnell, Scott R., et al.. (2024). Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease. Lupus Science & Medicine. 11(1). e001112–e001112. 10 indexed citations
4.
Askanase, Anca, Richard Furie, Maria Dall’Era, et al.. (2024). Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations. Lupus Science & Medicine. 11(1). e001124–e001124. 4 indexed citations
5.
Vollenhoven, Ronald van, Eric F. Morand, Richard Furie, et al.. (2024). LBO1 DORIS remission in patients with SLE treated with anifrolumab or placebo during the 4-year TULIP-LTE trial: post hoc analysis. SHILAP Revista de lepidopterología. A169–A170. 2 indexed citations
6.
Morand, Eric F., Ronald van Vollenhoven, Richard Furie, et al.. (2023). OP0051 LUPUS LOW DISEASE ACTIVITY STATE ATTAINMENT IN THE PHASE 3 PLACEBO-CONTROLLED TULIP LONG-TERM EXTENSION TRIAL OF ANIFROLUMAB. Annals of the Rheumatic Diseases. 82. 33–34. 5 indexed citations
7.
Furie, Richard, Maria Dall’Era, Andrew S. Bomback, et al.. (2023). AB0531 APPLYING THE WORKING DEFINITION OF THE DISEASE MODIFICATION CRITERIA TO LUPUS NEPHRITIS TREATMENTS FROM THE PUBLISHED LITERATURE. Annals of the Rheumatic Diseases. 82. 1463–1464. 1 indexed citations
8.
Jayne, David, Brad H. Rovin, Eduardo Mysler, et al.. (2023). Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial. Lupus Science & Medicine. 10(2). e000910–e000910. 23 indexed citations
9.
Furie, Richard. (2023). 09 Herpes zoster prevalence and recommendations from clinical trial safety data. SHILAP Revista de lepidopterología. A5.2–A6. 1 indexed citations
10.
Morand, Eric F., Gabriel Abreu, Richard Furie, Vera Golder, & Raj Tummala. (2023). Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. Annals of the Rheumatic Diseases. 82(5). 639–645. 36 indexed citations
11.
Bruce, Ian N, Ronald van Vollenhoven, Eric F. Morand, et al.. (2022). Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: apost hocanalysis of the TULIP-1 and TULIP-2 trials. Lara D. Veeken. 62(4). 1526–1534. 20 indexed citations
12.
Bruce, Ian N, Richard Furie, Eric F. Morand, et al.. (2022). Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Annals of the Rheumatic Diseases. 81(7). 962–969. 26 indexed citations
13.
Vollenhoven, Ronald van, Anca Askanase, Andrew S. Bomback, et al.. (2022). Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria. Lupus Science & Medicine. 9(1). e000634–e000634. 31 indexed citations
14.
Brunner, Hermine I., Carlos Abud‐Mendoza, Masaaki Mori, et al.. (2021). Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. RMD Open. 7(3). e001747–e001747. 19 indexed citations
15.
Furie, Richard, Ian N Bruce, Thomas Dörner, et al.. (2021). Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Lara D. Veeken. 60(11). 5397–5407. 79 indexed citations
16.
Wallace, Daniel J., Ellen M. Ginzler, Joan T. Merrill, et al.. (2019). Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. Arthritis & Rheumatology. 71(7). 1125–1134. 84 indexed citations
17.
Hui‐Yuen, Joyce, Jennifer Taylor, Xiaoqing Li, et al.. (2015). Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices. The Journal of Rheumatology. 42(12). 2288–2295. 75 indexed citations
18.
Proulle, Valérie, Richard Furie, Glenn Merrill‐Skoloff, Barbara C. Furie, & Bruce Furie. (2014). Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS. Blood. 124(4). 611–622. 84 indexed citations
19.
Kalunian, Kenneth, Winn Chatham, Elena Massarotti, et al.. (2012). Measurement of cell‐bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. Arthritis & Rheumatism. 64(12). 4040–4047. 62 indexed citations
20.
Kaplan, Stuart S., et al.. (1993). Monoclonal IgM, IgG, and IgA Human Rheumatoid Factors Produced by Synovial Tissue-Derived, EBV-Transformed B Cell Lines. Clinical Immunology and Immunopathology. 66(1). 18–25. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joan T. Merrill Breakdown of academic impact, for papers by William Stohl Breakdown of academic impact, for papers by Jill P. Buyon Breakdown of academic impact, for papers by Kenneth Kalunian Breakdown of academic impact, for papers by Ellen M. Ginzler Breakdown of academic impact, for papers by Frédéric Houssiau Breakdown of academic impact, for papers by Gunnar Sturfelt Breakdown of academic impact, for papers by Gabor G. Illei Breakdown of academic impact, for papers by Iva Gunnarsson Breakdown of academic impact, for papers by Anne Davidson
Rankless by CCL
2026